Septerna, Inc. (SEPN)

NASDAQ: SEPN · Real-Time Price · USD
25.62
+2.67 (11.63%)
Nov 6, 2024, 4:00 PM EST - Market closed
11.63%
Market Cap 1.08B
Revenue (ttm) 838,000
Net Income (ttm) -10.27M
Shares Out 42.00M
EPS (ttm) -4.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 330,032
Open 23.44
Previous Close 22.95
Day's Range 22.75 - 26.00
52-Week Range 18.62 - 26.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 15, 2024

About SEPN

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves’ disease and thyroid eye disease. It also develops o... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2024
Employees 68
Stock Exchange NASDAQ
Ticker Symbol SEPN
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral smal...

7 days ago - GlobeNewsWire

U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names

Three sizable IPOs priced this past week, joined by a flurry of small issuers and blank check companies - Ingram Micro, Septerna, and WeRide. Several small issuers also listed this past week, includin...

Other symbols: INGMLBGJPRBROLRSAGSNYR
11 days ago - Seeking Alpha

Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut

Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of $970 million.

12 days ago - Reuters

Septerna Prices Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral smal...

12 days ago - GlobeNewsWire

Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO

Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its upsized initial public offering in the United States.

13 days ago - Reuters

Biotech Septerna aims to raise up to $186 million in US IPO

Biotechnology company Septerna said on Monday it is aiming to raise up to $186 million in its initial public offering in the United States.

16 days ago - Reuters

Septerna Pursues $100 Million IPO For Endocrine And Metabolic Drug Pipeline

Septerna, Inc. aims to raise $100 million in an IPO to advance its clinical-stage biopharma treatments for endocrine diseases, with SEP-786 in Phase 1 trials. The hypoparathyroidism treatment market i...

4 weeks ago - Seeking Alpha

Septerna IPO Registration Document (S-1)

Septerna has filed to go public with an IPO on the NASDAQ.

5 weeks ago - SEC